Articles

P.01 A LUNG CANCER-DERIVED CRAF MUTATION IS ERK PATHWAY ACTIVATING AND PREDICTS SENSITIVITY TO COMBINED TYPE II RAF AND MEK INHIBITION

BJMO - volume 12, issue 3, february 2018

A. Noeparast PhD, J. De Grève MD, PhD, S. De Brakeleer PhD, P. Giron PhD, C. Eggermont , Rajendra Bahadur Shahi , E. Teugels PhD

Read more